wire - news in brief

« BACK

Pharmacology



Results 1 - 11 of 11.


Health - Pharmacology - 20.07.2021
Impaired humoral and cellular immune responses to SARSCov-2 mRNA vaccine in virus unexposed patients receiving maintenance hemodialysis
Impaired humoral and cellular immune responses to SARSCov-2 mRNA vaccine in virus unexposed patients receiving maintenance hemodialysis
The ROMANOV study found impaired humoral and cellular immune responses to SARSCov-2 mRNA vaccine in virus unexposed patients receiving maintenance hemodialysis The ROMANOV study found impaired humoral

Pharmacology - 22.03.2021
Massive clonal expansion of polycytotoxic skin and blood CD8+ T cells in patients with toxic epidermal necrolysis patients
Massive clonal expansion of polycytotoxic skin and blood CD8+ T cells in patients with toxic epidermal necrolysis patients
Publication of CIRI in Sciences advances on March 19, 2021. Toxic epidermal necrolysis (TEN) is a life-threatening cutaneous adverse drug reaction.

Health - Pharmacology - 15.04.2020
Covid-19: CIRI mobilizes its teams to understand the immune response against Coronavirus in patients
A CIRI project, in collaboration with HCL, has united CIRI immunologists to work on understanding the immune response to Coronavirus in patients.

Pharmacology - 25.11.2019
Missing self triggers NK cell-mediated chronic vascular rejection of solid organ transplants
Publication by CIRI on November 25, 2019. Dogma in transplantation holds that microvascular inflammation (MVI) triggered by recipient's antibody response against alloantigens (antibody-mediated rejection) is the main cause of graft failure.

Health - Pharmacology - 27.05.2019
Inhibitory checkpoint receptors control CD8+ resident memory T cells to prevent skin allergy
Publication by the International Center for Infectiology Research (CIRI) in The Journal of Allergy and Clinical Immunology on January 14, 2019.

Pharmacology - Life Sciences - 11.05.2018
Farnesoid X receptor-- is a proviral host factor for hepatitis B virus that is inhibited by ligands in vitro and in vivo
Farnesoid X receptor- is a proviral host factor for hepatitis B virus that is inhibited by ligands in vitro and in vivo Abstract: Hepatitis B virus (HBV) infection and bile acid (BA) metabolism are in